77181-69-2

Usage

Uses

Used in Antiviral Applications:
Sorivudine is used as an antiviral agent for the treatment of diseases caused by herpes simplex virus type-1 (HSV-1) and varicella-zoster virus (VZV). It demonstrates significant antiviral activity, particularly in cutaneous model infections of mice with HSV-1, where oral administration at a dose of 20 mg/kg resulted in a substantial increase in the survival rate.
Used in Topical Treatment:
Sorivudine is used as a topical treatment for cutaneous HSV-1 infection, including immunocompromised patients. A 5% sorivudine cream has been found useful in managing such infections.
Used in Pharmaceutical Industry:
Sorivudine is used as a key component in the synthesis of antiviral compounds, contributing to the development of new drugs for the treatment of viral diseases.
Precaution:
Sorivudine's metabolite inhibits the enzyme responsible for pyrimidine catabolism. Therefore, it is crucial not to use sorivudine in combination with fluorouracil drugs to avoid hematological disorders.
Brand Names:
Bravavir (Bristol-Myers Squibb); Usevir.

Originator

Yamasa Shoyu (Japan)

InChI:InChI=1/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8+,10-/m1/s1

Upstream product

• 86359-94-6 Acetic acid (2R,3S,4R,5R)-4-acetoxy-5-acetoxymethyl-2-[5-((Z)-2-bromo-vinyl)-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl]-tetrahydro-furan-3-yl ester 
• 87877-27-8 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)-5-(E)-2-(bromovinyl)uracil 
• 132054-88-7 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)-5-(Z)-<2-(trimethylsilyl)vinyl>uracil 
• 95119-95-2 3-(1-(β-D-arabinofuranosyl)uracil-5-yl)-acrylic acid 

Downstream Products

• 150464-65-6 1-(2,3,5-tri-O-benzoyl-β-D-arabinofuranosyl)-5(E)-(2-bromovinyl)uracil 
• 80434-16-8 5-((Z)-2-Bromo-vinyl)-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione 

Relevant academic research and scientific papers

NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY

The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytostatic treatment of a cancer patient.

Nucleoside analogue phosphates for topical use

Compositions for topical use in herpes virus infections comprising anti-herpes nucleoside analogue phosphate esters, such as acyclovir monophosphate, acyclovir diphosphate, and acyclovir triphosphate which show increased activity against native strains of herpes virus as well as against resistant strains, particularly thymidine kinase negative strains of virus. Also disclosed are methods for treatment of herpes infections with nucleoside phosphates. Anti-herpes nucleoside analogues phosphate esters include the phosphoramidates and phosphothiorates, as well as polyphosphates comprising C and S bridging atoms.

Facile access to 2′-O-acyl prodrugs of 1- (β-D-arabinofuranosyl)-5(E)-(2-bromovinyl)uracil (BVAraU) via regioselective esterase-catalyzed hydrolysis of 2′ 3′, 5′-triesters

Treatment of 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl) -5-[2-(trimethylsilyl)-vinyl]uracil (3) with pyridinium bromide perbromide and deacetylation gave BVAraU (2). Pig liver esterase (EC 3.1.1.1) catalysed the regioselective hydrolysis of 1-

Conversion of vinylsilanes to vinyl halides with xenon difluoride and metal halides. A versatile new route to 5-(2-halovinyl)pyrimidine nucleosides

Addition of a protected 5-(2-trimethylsilylvinyl)uracil nucleoside to suspensions of xenon difluoride and alkali metal halides in benzene (or other solvents) resulted in rapid formation of the corresponding 5-(2-halovinyl)uracil products (E-isomer predominating).